Table 1.
Patient characteristics and previous treatment for nephrotic syndrome
| Patient characteristics | MMF | CsA | p |
|---|---|---|---|
| Number of patients | 12 | 12 | |
| Male | 10 | 11 | 1.00 |
| Age (years) | 10.9 (4.0–15.2) | 9.2 (3.7–17.5) | 0.81 |
| Duration of nephrotic syndrome (years) | 5.3 (1.1–11.4) | 5.2 (1.1–12.3) | 0.99 |
| Steroid dependency | 8 | 8 | 1.00 |
| Previous treatment | |||
| Cyclophosphamide | 12 | 11 | 1.00 |
| Months before study entry | 22 (5–103) | 47 (5–153) | 0.65 |
| Levamisole | 0 | 1 | |
| CsA | 5 | 6 | 1.00 |
| Duration of CsA medication (years) | 2.2 (1.4–3.2) | 4.0 (1–10) | 0.51 |
Data are given as number of patients or as the median, with the range in parenthesis
MMF Mycophenolate mofetil; CsA cyclosporine A